☆ 4.1 Editorial Material

Immunization, not vaccination: monoclonal antibodies for infant RSV prevention and the US vaccines for children program

JOURNAL OF MEDICAL ECONOMICS (2023)

Related references

Note: Only part of the references are listed.

Article Pediatrics

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials

Eric A. F. Simoes et al.

Summary: This study evaluated the efficacy of nirsevimab using a weight-banded dosing regimen in infants born between 29 weeks gestational age and full term. The results showed that a single dose of nirsevimab protected healthy infants born at term or preterm from RSV lower respiratory tract infection, reducing the incidence of hospital admissions and severe cases associated with RSV. Therefore, nirsevimab has the potential to alleviate the burden of infant RSV disease.

LANCET CHILD & ADOLESCENT HEALTH (2023)

Add to Collection

Article Medicine, General & Internal

Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants

B. Kampmann et al.

Summary: Vaccination of pregnant women with RSVpreF vaccine was effective in reducing severe RSV-associated lower respiratory tract illness in infants. The vaccine showed 81.8% efficacy within 90 days and 69.4% efficacy within 180 days. The vaccine was found to be safe for both mothers and infants.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

Laura L. Hammitt et al.

Summary: A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

Joseph Domachowske et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Immunology

RSV Prevention in All Infants: Which Is the Most Preferable Strategy?

Susanna Esposito et al.

Summary: Respiratory syncytial virus (RSV) is a major cause of respiratory illnesses in infants and young children, resulting in significant economic and healthcare burden. The currently available preventative strategy, palivizumab, only protects a subset of the infant population, leaving the majority unprotected. Therefore, developing effective prevention strategies for all infants is crucial.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

News Item Medicine, General & Internal

RSV: UK to examine whether to offer monoclonal antibody routinely to all babies

Jacqui Wise

BMJ-BRITISH MEDICAL JOURNAL (2022)

Add to Collection

Article Immunology

Respiratory Syncytial Virus Is the Leading Cause of United States Infant Hospitalizations, 2009-2019: A Study of the National (Nationwide) Inpatient Sample

Mina Suh et al.

Summary: This study demonstrates that acute bronchiolitis due to RSV is the leading cause of hospitalizations in US infants, especially during the winter months.

JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Review Immunology

Impact of Respiratory Syncytial Virus on Child, Caregiver, and Family Quality of Life in the United States: Systematic Literature Review and Analysis( )

Elizabeth L. Glaser et al.

Summary: This study systematically reviewed and analyzed the burden of illness from respiratory syncytial virus (RSV) among infants. The results indicated that RSV reduces the quality of life of children, caregivers, and families. However, the existing data mainly focus on hospitalized premature infants, and more research is needed for full-term healthy children.

JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Review Immunology

Cost of Respiratory Syncytial Virus Infections in US Infants: Systematic Literature Review and Analysis

Diana M. Bowser et al.

Summary: This study examines the economic costs of respiratory syncytial virus (RSV) infections among infants and young children in the United States. The findings suggest that public sources bear the majority of the medical costs associated with infants' RSV treatment, and full-term infants account for the majority of RSV hospitalizations and costs.

JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Article Pediatrics

The assessment of future RSV immunizations: How to protect all infants?

Louis Bont et al.

FRONTIERS IN PEDIATRICS (2022)

Add to Collection

Article Respiratory System

Estimated incidence of respiratory hospitalizations attributable to RSV infections across age and socioeconomic groups

Zhe Zheng et al.

Summary: Respiratory syncytial virus (RSV) causes a significant burden of hospitalization in the US, particularly among infants and older adults. The incidence is higher among infants of low socioeconomic status and varies among different socioeconomic groups. Recorded diagnoses underestimate the incidence of RSV hospitalization, especially in older adults.

PNEUMONIA (2022)

Add to Collection

Review Immunology

Ethics of Vaccination in Childhood-A Framework Based on the Four Principles of Biomedical Ethics

Meta Rus et al.

Summary: Vaccination is considered the top public health achievement of the 20th century, but in countries with established immunisation programmes, the success of vaccines has reduced the perceived historical burden of disease. The increasing number of vaccine-hesitant individuals has led to decreased herd immunity levels and outbreaks of previously controlled diseases. A framework for ethical analysis based on the principles of biomedical ethics is proposed to address the ethical aspects of vaccination at both individual and societal levels.

VACCINES (2021)

Add to Collection

Article Infectious Diseases

Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study

You Li et al.

Summary: In LMICs with clear RSV seasonality, seasonal approaches to monoclonal antibody and maternal vaccine administration may optimize disease prevention by dose given compared with year-round administration.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Review Immunology

Bringing Preventive RSV Monoclonal Antibodies to Infants in Low- and Middle-Income Countries: Challenges and Opportunities

Jintanat Ananworanich et al.

Summary: RSV is the leading cause of acute lower respiratory tract infections in infants, with high mortality rates in LMICs. While there are no approved infant RSV vaccines, monoclonal antibodies could provide a temporary solution. Efficient manufacturing and collaboration with key stakeholders will be essential in making RSV monoclonal antibodies more accessible in LMICs.

VACCINES (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China

Yanbing Zeng et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)

Add to Collection

Article Multidisciplinary Sciences

Two new medicines may curb serious respiratory disease in infants

Jon Cohen

SCIENCE (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Scientific and Ethical Principles Underlying Recommendations From the Advisory Committee on Immunization Practices for COVID-19 Vaccination Implementation

Beth P. Bell et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Infectious Diseases

Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15

Carmen S. Arriola et al.

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2020)

Add to Collection

Review Pediatrics

Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review

Stephen Mac et al.

PEDIATRICS (2019)

Add to Collection

Letter Infectious Diseases

Respiratory Syncytial Virus-Associated Outpatient Visits Among Children Younger Than 24 Months

Joana Y. Lively et al.

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2019)

Add to Collection

Review Immunology

Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies

Barnaby Young et al.

JOURNAL OF INFECTIOUS DISEASES (2018)

Add to Collection

Article Public, Environmental & Occupational Health

Respiratory Syncytial Virus Seasonality - United States, 2014-2017

Erica Billig Rose et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)

Add to Collection

Article Respiratory System

The Economic Burden of Asthma in the United States, 2008-2013

Tursynbek Nurmagambetov et al.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2018)

Add to Collection

Article Medicine, General & Internal

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

Ting Shi et al.

LANCET (2017)

Add to Collection

Article Immunology

Effectiveness of Palivizumab in High-risk Infants and Children A Propensity Score Weighted Regression Analysis

Evan J. Anderson et al.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2017)

Add to Collection

Article Infectious Diseases

Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States

Rohan C. Parikh et al.

INFECTIOUS DISEASES AND THERAPY (2017)

Add to Collection

Article Pediatrics

Respiratory Syncytial Virus-Associated Hospitalizations Among Children Less Than 24 Months of Age

Caroline Breese et al.

PEDIATRICS (2013)

Add to Collection

Editorial Material Medicine, General & Internal

Monoclonal antibodies: magic bullets with a hefty price tag

Allen F. Shaughnessy

BRITISH MEDICAL JOURNAL (2012)

Add to Collection

Article Medicine, General & Internal

Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants

Nianwen Shi et al.

JOURNAL OF MEDICAL ECONOMICS (2011)

Add to Collection

Article Medicine, General & Internal

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

Harish Nair et al.

LANCET (2010)

Add to Collection

Review Medicine, General & Internal

Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systemic review and meta-analysis

CF Lee et al.

BMJ-BRITISH MEDICAL JOURNAL (2006)

Add to Collection

Article Economics

Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants

S Leader et al.

VALUE IN HEALTH (2003)

Add to Collection

Article Multidisciplinary Sciences

Imperfect vaccines and the evolution of pathogen virulence

S Gandon et al.

NATURE (2001)

Add to Collection

Article Pediatrics

Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid

TG Boyce et al.

JOURNAL OF PEDIATRICS (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.